A5103076894- Protein Degradation and Inhibitors
- Genomics and Chromatin Dynamics
- Colorectal Cancer Treatments and Studies
- Heat shock proteins research
- Advanced Breast Cancer Therapies
- Viral Infectious Diseases and Gene Expression in Insects
- Radiomics and Machine Learning in Medical Imaging
- Medical Imaging and Pathology Studies
- Melanoma and MAPK Pathways
- Pediatric Pain Management Techniques
- Computational Drug Discovery Methods
- Colorectal Cancer Surgical Treatments
- Viral gastroenteritis research and epidemiology
- HER2/EGFR in Cancer Research
- Sarcoma Diagnosis and Treatment
- Virus-based gene therapy research
- Inflammatory mediators and NSAID effects
- Angiogenesis and VEGF in Cancer
- Monoclonal and Polyclonal Antibodies Research
- CAR-T cell therapy research
- Histone Deacetylase Inhibitors Research
- Pancreatic and Hepatic Oncology Research
- Hepatocellular Carcinoma Treatment and Prognosis
- Multiple and Secondary Primary Cancers
- NF-κB Signaling Pathways
Arvinas (United States)
2024
University of Alberta
2014
Alcon (United Kingdom)
2013
Sunderland Royal Hospital
2012
Bayer (Germany)
2000-2007
Bayer (Italy)
2006
Memorial Sloan Kettering Cancer Center
2006
Bayer (United States)
2004-2006
Bradford Royal Infirmary
2006
Tel Aviv Sourasky Medical Center
2006
The RAS/RAF signaling pathway is an important mediator of tumor cell proliferation and angiogenesis. novel bi-aryl urea BAY 43-9006 a potent inhibitor Raf-1, member the RAF/MEK/ERK pathway. Additional characterization showed that suppresses both wild-type V599E mutant BRAF activity in vitro. In addition, demonstrated significant against several receptor tyrosine kinases involved neovascularization progression, including vascular endothelial growth factor (VEGFR)-2, VEGFR-3, platelet-derived...
This phase II study of sorafenib, an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases, assessed efficacy, toxicity, pharmacokinetics, biomarkers in advanced hepatocellular carcinoma (HCC) patients.Patients with inoperable HCC, no prior systemic treatment, Child-Pugh (CP) A or B, received continuous, sorafenib 400 mg bid 4-week cycles. Tumor response was every two cycles using modified WHO criteria. Sorafenib pharmacokinetics were measured plasma samples....
Abstract Purpose: Estrogen receptor (ER) alpha signaling is a known driver of ER-positive (ER+)/human epidermal growth factor 2 negative (HER2−) breast cancer. Combining endocrine therapy (ET) such as fulvestrant with CDK4/6, mTOR, or PI3K inhibitors has become central strategy in the treatment ER+ advanced However, suboptimal ER inhibition and resistance resulting from ESR1 mutation dictates that new therapies are needed. Experimental Design: A medicinal chemistry campaign identified...
Regulatory factors must contend with chromatin structure to function. Although nucleosome and position on promoters can be important in determining factor access, the intrinsic ability of bind nucleosomal DNA might also play an essential regulatory role. We have used templates where nucleosomes were either randomly positioned or rotationally phased demonstrate that two transcription factors, heat shock (HSF) GAL4, differ significantly their nucleosomes. GAL4 was able templates. Surprisingly,...
The human heat shock protein 70 (hsp70) gene is expressed constitutively in a wide variety of cells. Two separate promoter domains determine this basal level hsp70 expression. proximal domain contained within 84 bases the transcription initiation site and consists three elements which appear to interact with TATA factor(s) CCAAT-box-binding factor SP1, respectively. sufficient for near-maximal expression rodent cell lines. distal sequences upstream -84 necessary conjunction full Although...
<div>Abstract<p>Androgen receptor (AR) signaling is the principal driver of prostate cancer, and drugs that target this pathway (e.g., abiraterone enzalutamide) are standard treatments for metastatic hormone-sensitive cancer castration-resistant cancer. However, continual evolution during progression can result in <i>AR</i> alterations mutation, amplification, splicing) cause tumors to become resistant these therapies. Bavdegalutamide (ARV-110) a PROteolysis TArgeting...
<p>Supplementary Figure S2 shows the effect of bavdegalutamide on neomorphic substrates</p>
<p>Supplementary Figure S3 shows the effect of bavdegalutamide on SALL4</p>
<p>Supplementary Figure S4 shows maintenance of animal body weights during treatment with bavdegalutamide or enzalutamide in prostate cancer mouse models</p>
<p>Supplementary Figure S1 shows the effect of bavdegalutamide on AR versus AR-V7</p>
S M Liao, I C Taylor, R E Kingston, and A Young Whitehead Institute for Biomedical Research, Cambridge, Massachusetts 02142.
To investigate interactions between transcription factors on mammalian promoters, we constructed a set of 24 variations the human HSP70 gene promoter in which six upstream sequence motifs are paired every possible combination with four TATA motifs. These promoters were analyzed for vivo expression, and selected constructs examined by vitro template commitment studies. Activation factor (ATF) CP1 showed dramatically different factor(s) bound to region. functioned regardless motif that it was...
The human heat shock protein 70 (hsp70) gene is expressed constitutively in a wide variety of cells. Two separate promoter domains determine this basal level hsp70 expression. proximal domain contained within 84 bases the transcription initiation site and consists three elements which appear to interact with TATA factor(s) CCAAT-box-binding factor SP1, respectively. sufficient for near-maximal expression rodent cell lines. distal sequences upstream -84 necessary conjunction full Although...
To gain insight into the signal transduction pathways utilized by Wnt-1-responsive mammary epithelial cell line C57MG, we screened for non-src family member tyrosine kinases expressed in these cells using a polymerase chain reaction-based technique. We identified five cDNA clones encoding receptor which ligand is known (fibroblast growth factor receptor, platelet-derived insulin and insulin-like receptor), two putative remains to be (the products of ryk mouse klg homolog), novel kinase....
To investigate interactions between transcription factors on mammalian promoters, we constructed a set of 24 variations the human HSP70 gene promoter in which six upstream sequence motifs are paired every possible combination with four TATA motifs. These promoters were analyzed for vivo expression, and selected constructs examined by vitro template commitment studies. Activation factor (ATF) CP1 showed dramatically different factor(s) bound to region. functioned regardless motif that it was...
<div>AbstractPurpose:<p>Estrogen receptor (ER) alpha signaling is a known driver of ER-positive (ER<sup>+</sup>)/human epidermal growth factor 2 negative (HER2<sup>−</sup>) breast cancer. Combining endocrine therapy (ET) such as fulvestrant with CDK4/6, mTOR, or PI3K inhibitors has become central strategy in the treatment ER<sup>+</sup> advanced However, suboptimal ER inhibition and resistance resulting from <i>ESR1</i> mutation...